BAJAJ BROKING

Notification
No new Notification messages
Tankup Engineers IPO is Open!
Apply for the Tankup Engineers IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

536565

NOVELIX

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

NOVELIX PHARMACEUTICALS LIMITE Share Price Update

As of the latest trading session, NOVELIX PHARMACEUTICALS LIMITE share price is currently at ₹ 26.61, which is up by 0.00 from its previous closing. Today, the stock has fluctuated between ₹ 26.61 and ₹ 26.61. Over the past year, NOVELIX PHARMACEUTICALS LIMITE has achieved a return of 54.79 %. In the last month alone, the return has been 0.00 %. Read More...

NOVELIX PHARMACEUTICALS LIMITE fundamentals


  • Market cap (Cr)

  • P/E Ratio (TTM)

  • Beta

  • Book Value / share

  • Return on equity

    %

  • EPS (TTM)

  • Dividend yield

    %

  • Net profit/quarter (Cr)

info icon alternate text
  • Market cap (Cr)

    21.55

  • P/E Ratio (TTM)

    332.63

  • Beta

    -0.06

  • Book Value / share

    15.62

  • Return on equity

    -0.24%

  • EPS (TTM)

    0.08

  • Dividend yield

    %

  • Net profit/quarter (Cr)

    0.15

info icon alternate text

NOVELIX PHARMACEUTICALS LIMITE Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 5.30
Operating Expense 5.17
Net Profit 0.15
Net Profit Margin (%) 2.83
Earnings Per Share (EPS) 0.15
EBITDA 0.13
Effective Tax Rate (%) -15.38
Particulars SEP 2024 (Values in Cr)
Revenue 3.96
Operating Expense 3.74
Net Profit 0.13
Net Profit Margin (%) 3.28
Earnings Per Share (EPS) 0.16
EBITDA 0.13
Effective Tax Rate (%) 0.00
Particulars JUN 2024 (Values in Cr)
Revenue 0.60
Operating Expense 1.04
Net Profit -0.35
Net Profit Margin (%) -58.33
Earnings Per Share (EPS) -0.43
EBITDA -0.35
Effective Tax Rate (%) -2.85
Particulars MAR 2024 (Values in Cr)
Revenue 0.84
Operating Expense 0.69
Net Profit 0.28
Net Profit Margin (%) 33.33
Earnings Per Share (EPS) 0.34
EBITDA 0.29
Effective Tax Rate (%) 0.00
Particulars DEC 2023 (Values in Cr)
Revenue 0.50
Operating Expense 0.62
Net Profit -0.03
Net Profit Margin (%) -6.00
Earnings Per Share (EPS) -0.04
EBITDA -0.01
Effective Tax Rate (%) 0.00
Particulars MAR 2024 (Values in Cr)
Revenue 4.22
Operating Expense 4.51
Net Profit 0.01
Net Profit Margin (%) 0.23
Earnings Per Share (EPS) 0.01
EBITDA 0.06
Effective Tax Rate (%) 50.00
Particulars MAR 2023 (Values in Cr)
Revenue 1.40
Operating Expense 1.98
Net Profit -0.06
Net Profit Margin (%) -4.28
Earnings Per Share (EPS) -0.07
EBITDA 0.00
Effective Tax Rate (%) 0.00
Particulars MAR 2022 (Values in Cr)
Revenue 0.84
Operating Expense 2.96
Net Profit -1.56
Net Profit Margin (%) -185.71
Earnings Per Share (EPS) -1.93
EBITDA -1.50
Effective Tax Rate (%) 0.63
Particulars MAR 2021 (Values in Cr)
Revenue 0.99
Operating Expense 4.58
Net Profit -3.27
Net Profit Margin (%) -330.30
Earnings Per Share (EPS) -4.04
EBITDA -3.19
Effective Tax Rate (%) 0.00
Particulars MAR 2020 (Values in Cr)
Revenue 1.03
Operating Expense 1.40
Net Profit 0.09
Net Profit Margin (%) 8.73
Earnings Per Share (EPS) 0.12
EBITDA 0.19
Effective Tax Rate (%) 9.09
Particulars MAR 2022 (Values in Cr)
Book Value / Share 9.14
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.01
EBITDA Margin -20.22
Particulars MAR 2021 (Values in Cr)
Book Value / Share 8.47
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.04
EBITDA Margin -36.18
Particulars MAR 2020 (Values in Cr)
Book Value / Share 13.09
ROE % -2.42
ROCE % -0.86
Total Debt to Total Equity 0.08
EBITDA Margin 0.92
Particulars MAR 2019 (Values in Cr)
Book Value / Share 13.48
ROE % -1.54
ROCE % -0.93
Total Debt to Total Equity 0.09
EBITDA Margin 1.00
Particulars MAR 2018 (Values in Cr)
Book Value / Share 13.79
ROE % -2.99
ROCE % -0.07
Total Debt to Total Equity 0.09
EBITDA Margin 2.16
Particulars MAR 2024 (Values in Cr)
Book Value / Share 9.08
ROE % -0.24
ROCE % -0.24
Total Debt to Total Equity 0.00
EBITDA Margin 0.44
Particulars MAR 2023 (Values in Cr)
Book Value / Share 8.88
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin 0.00
Particulars MAR 2022 (Values in Cr)
Book Value / Share 8.94
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin -107.19
Particulars MAR 2021 (Values in Cr)
Book Value / Share 10.87
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin -243.51
Particulars MAR 2020 (Values in Cr)
Book Value / Share 14.90
ROE % 0.75
ROCE % 0.83
Total Debt to Total Equity 0.00
EBITDA Margin 12.00
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 2.88
Total Assets 8.73
Total Liabilities 8.73
Total Equity 7.67
Share Outstanding 8100000
Price to Book Ratio 0.99
Return on Assets (%) -20.60
Return on Capital (%) -23.05
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 2.07
Total Assets 9.57
Total Liabilities 9.57
Total Equity 7.36
Share Outstanding 8100000
Price to Book Ratio 0.62
Return on Assets (%) -39.06
Return on Capital (%) -50.77
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 1.11
Total Assets 13.72
Total Liabilities 13.72
Total Equity 11.12
Share Outstanding 8100000
Price to Book Ratio 0.13
Return on Assets (%) -2.06
Return on Capital (%) -2.38
Particulars MAR 2019 (Values in Cr)
Cash & Short Term Investments 0.19
Total Assets 13.34
Total Liabilities 13.34
Total Equity 11.42
Share Outstanding 8100000
Price to Book Ratio 0.00
Return on Assets (%) -1.81
Return on Capital (%) -1.96
Particulars MAR 2018 (Values in Cr)
Cash & Short Term Investments 0.35
Total Assets 13.57
Total Liabilities 13.57
Total Equity 11.57
Share Outstanding 8100000
Price to Book Ratio 0.52
Return on Assets (%) -2.56
Return on Capital (%) -2.77
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 0.11
Total Assets 7.36
Total Liabilities 7.36
Total Equity 7.35
Share Outstanding 8100000
Price to Book Ratio 1.89
Return on Assets (%) 0.14
Return on Capital (%) 0.14
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 0.27
Total Assets 7.25
Total Liabilities 7.25
Total Equity 7.19
Share Outstanding 8100000
Price to Book Ratio 1.01
Return on Assets (%) -0.82
Return on Capital (%) -0.83
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 2.60
Total Assets 7.25
Total Liabilities 7.25
Total Equity 7.24
Share Outstanding 8100000
Price to Book Ratio 0.99
Return on Assets (%) -21.51
Return on Capital (%) -21.54
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 1.73
Total Assets 8.76
Total Liabilities 8.76
Total Equity 8.80
Share Outstanding 8100000
Price to Book Ratio 0.62
Return on Assets (%) -37.28
Return on Capital (%) -37.13
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 0.95
Total Assets 12.03
Total Liabilities 12.03
Total Equity 12.07
Share Outstanding 8100000
Price to Book Ratio 0.13
Return on Assets (%) 0.78
Return on Capital (%) 0.79
Particulars MAR 2022 (Values in Cr)
Net Income -2.12
Cash from Operations 1.10
Cash from Investing -0.75
Cash from Financing 0.00
Net change in Cash 0.82
Free Cash Flow 2.90
Particulars MAR 2021 (Values in Cr)
Net Income -3.72
Cash from Operations 1.62
Cash from Investing 0.13
Cash from Financing -0.76
Net change in Cash 0.96
Free Cash Flow 1.64
Particulars MAR 2020 (Values in Cr)
Net Income -0.21
Cash from Operations 0.73
Cash from Investing 0.45
Cash from Financing -0.16
Net change in Cash 0.91
Free Cash Flow 0.83
Particulars MAR 2019 (Values in Cr)
Net Income -0.12
Cash from Operations -0.52
Cash from Investing 0.42
Cash from Financing -0.04
Net change in Cash -0.15
Free Cash Flow -0.38
Particulars MAR 2018 (Values in Cr)
Net Income -0.30
Cash from Operations 0.49
Cash from Investing -0.63
Cash from Financing 0.02
Net change in Cash -0.24
Free Cash Flow 0.86
Particulars MAR 2024 (Values in Cr)
Net Income 0.02
Cash from Operations -0.34
Cash from Investing 0.18
Cash from Financing 0.00
Net change in Cash -0.15
Free Cash Flow -0.34
Particulars MAR 2023 (Values in Cr)
Net Income -0.05
Cash from Operations -2.40
Cash from Investing 0.07
Cash from Financing 0.00
Net change in Cash -2.33
Free Cash Flow -2.40
Particulars MAR 2022 (Values in Cr)
Net Income -1.56
Cash from Operations 0.59
Cash from Investing 0.27
Cash from Financing 0.00
Net change in Cash 0.86
Free Cash Flow 2.45
Particulars MAR 2021 (Values in Cr)
Net Income -3.27
Cash from Operations 0.58
Cash from Investing 0.20
Cash from Financing 0.00
Net change in Cash 0.78
Free Cash Flow 0.88
Particulars MAR 2020 (Values in Cr)
Net Income 0.10
Cash from Operations 1.25
Cash from Investing -0.41
Cash from Financing 0.00
Net change in Cash 0.79
Free Cash Flow 1.27
Company Name Price P/E P/B Market Cap 52 Week Low/High
ALFRED HERBERT (INDIA) LTD. 2055.75 25.01 1.29 158.29 1125.25 / 2350.00
BAJAJ HOLDINGS & INVS LTD 11963.35 17.73 2.22 133140.12 7667.15 / 13221.50
TATA INVESTMENT CORP LTD 6291.25 95.06 0.86 31830.77 5147.15 / 8075.90
MAX FINANCIAL SERV LTD 1218.30 166.89 8.13 42045.33 864.30 / 1311.20
Company Name Price P/E P/B Market Cap 52 Week Low/High
ALFRED HERBERT (INDIA) LTD. 2055.75 25.40 1.44 158.29 1125.25 / 2350.00
ARAVALI SECURITIES & FINANCE L 3.90 0.00 -7.64 5.91 3.44 / 7.89
Bagalkot Udyog Ltd 23.90 0.00 -27.43 20.32 0.00 / 0.00
BAJAJ HOLDINGS & INVS LTD 11963.35 55.35 6.50 133140.12 7667.15 / 13221.50

NOVELIX PHARMACEUTICALS LIMITE Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
26.61 0.00 redarrow
red-green-graph indicator
16 Bearish
0 Bullish
  • 5 Days 26.50
  • 26 Days 24.50
  • 10 Days 26.10
  • 50 Days 22.20
  • 12 Days 25.90
  • 100 Days 18.70
  • 20 Days 25.10
  • 200 Days 15.30
26.61 PIVOT

First Support

26.61

First Resistance

26.61

Second Support

26.61

Second Resistance

26.61

Third Support

26.61

Third Resistance

26.61

RSI

0.00

ADX

100.00

MACD

1.40

Williams % R

0.00

Commodity Channel Index (CCI)

105.29

Date

2025-04-15

Week

20102.00

Same Day

20102.00

Month

5298.00

1 Year

-0.06

3 Year

-0.25

Over 1 Month

0.00%

down

Over 1 Year

54.79%

down

Over 3 Months

10.18%

down

Over 3 Years

43.90%

down

Over 6 Months

21.45%

down

Over 5 Years

67.30%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

NOVELIX PHARMACEUTICALS LIMITE shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
33.43%
Promoter Holdings
66.56%
FII
0.0%
DII
0.0%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Srinidhi Fine-chemicals Llp 5002000.0 (50.27%) Shareholding of Promoter and Promoter Group
Vupparapalli Chandrasekhar Reddy 870733.0 (8.75%) Shareholding of Promoter and Promoter Group
Vupparapalli Pavani 400000.0 (4.02%) Shareholding of Promoter and Promoter Group
Tdpl Health Care (india) Llp 350000.0 (3.52%) Public Shareholding
Gattu Gnana Prakash 350000.0 (3.52%) Shareholding of Promoter and Promoter Group
Soura Investments Holdings Private Limited 270000.0 (2.71%) Public Shareholding
Dm Fincon Services Llp 250000.0 (2.51%) Public Shareholding
Panchagnula Venkata Lakshmi Narayana Sankara Vara Prasad 225000.0 (2.26%) Public Shareholding
Medo Capital Services Private Limited 125000.0 (1.26%) Public Shareholding
Sesha Sai Nikhil Chintalapati 100000.0 (1.01%) Public Shareholding
Srinivasrao Swetha Kanakapur 100000.0 (1.01%) Public Shareholding

News

Left Arrow
Right Arrow

NOVELIX PHARMACEUTICALS LIMITE corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
16 Aug 2012 0.3 Final 21 Aug 2012 Equity shares
22 Sep 2011 0.3 Final 25 Sep 2011 Equity shares
23 Aug 2010 0.03 Final 25 Aug 2010 Equity shares
01 Sep 2009 0.3 Final 03 Sep 2009 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
04 Oct 2010 1.0 10.0 05 Oct 2010
15 Oct 2009 10.0 1.0 16 Oct 2009

NOVELIX PHARMACEUTICALS LIMITE Share Price

Trimurthi Limited was formerly incorporated on December 13, 1994 with the name Trimurthi Securities Ltd. The name of the Company thereafter got changed from Trimurthi Securities Ltd to Trimurthi Drugs & Pharmaceuticals Ltd. In September 2006, as per the Scheme of Arrangement, the erstwhile Trimurthi Drugs & Pharmaceuticals Ltd amalgamated with the Company. Also, the name of the Company was changed to Trimurthi Drugs & Pharmaceuticals Ltd and again to Trimurthi Limited in May, 2016.

Initially, the company was engaged in finance and investments in securities. They ceased their operations due to the high volatility in the markets and voluntarily got de-registered as Non-Banking financial company. Thereafter, the company explored the possibilities of entering into pharmaceutical and drug industry by way of diversification.

In November 2009, the Company received NS-EN ISO 9001:2008 / ISO 9001:2008 for marketing and distribution of pharmaceutical products from 'Kvalitet Veritas Quality Assurance'. They had been appointed as Authorized Distributors on all India level for Livewell Food products and ABLE, Pharma, in the Salon District of Himachal Pradesh.

During the year 2010-11, the Company started their first Pharmacy Retail Outlet in Himayath Nagar, Hyderabad. Also, they started their second retail outlet at Inderbagh, Sultan Bazar, Hyderabad. The Company with its full capacity commenced the business operations in food industry business through its wholly owned subsidiary in 2018.

The Company started their operations in State of West Bengal. Also, they started marketing of their products in Assam and with that they marked their presence in the eastern part of India.

Parent organization Indian Private
NSE symbol [-]
Founded 1994
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Novelix Pharmaceuticals Ltd?

Answer Field

The share price of Novelix Pharmaceuticals Ltd for NSE is ₹ 0.00 and for BSE is ₹ 26.61.

What is the Market Cap of Novelix Pharmaceuticals Ltd?

Answer Field

The market cap of Novelix Pharmaceuticals Ltd for NSE is ₹ 0.0 Cr. and for BSE is ₹ 66.40 Cr. as of now.

What is the 52 Week High and Low of Novelix Pharmaceuticals Ltd?

Answer Field

The 52 Week High and Low of Novelix Pharmaceuticals Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 26.61 and ₹ 17.19.

How to Buy Novelix Pharmaceuticals Ltd share?

Answer Field

You can trade in Novelix Pharmaceuticals Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Novelix Pharmaceuticals Ltd?

Answer Field

The 1 year returns on the stock has been 54.79%.

What is the Current Share Price of Novelix Pharmaceuticals Ltd?

Answer Field

Novelix Pharmaceuticals Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 26.61 as on Apr 21 2025 12:00 AM.

What is the Market Cap of Novelix Pharmaceuticals Ltd Share?

Answer Field

The market cap of Novelix Pharmaceuticals Ltd for NSE ₹ 0.0 & for BSE ₹ 66.40 as on Apr 21 2025 12:00 AM.

What is the P/E Ratio of Novelix Pharmaceuticals Ltd Share?

Answer Field

As on Apr 21 2025 12:00 AM the price-to-earnings (PE) ratio for Novelix Pharmaceuticals Ltd share is 332.63.

What is the PB ratio of Novelix Pharmaceuticals Ltd Share?

Answer Field

As on Apr 21 2025 12:00 AM, the price-to-book (PB) ratio for Novelix Pharmaceuticals Ltd share is 15.62.

How to Buy Novelix Pharmaceuticals Ltd Share?

Answer Field

You can trade in Novelix Pharmaceuticals Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Novelix Pharmaceuticals Ltd Share on Bajaj Broking App?

Answer Field

To buy Novelix Pharmaceuticals Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Novelix Pharmaceuticals Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|